 |
Journal articles
Doxorubicin Drug-Eluting Embolic Chemoembolization of Hepatocellular Carcinoma: Study of Midterm Doxorubicin Delivery in Resected Liver Specimens
Hadrien D’inca
1
Olivier Piot
1
Marie-Danièle Diebold
2
Tullio Piardi
3
Claude Marcus
4
Frédéric Burde
Daniele Sommacale
3
Michel Manfait
5
Gerard Thiefin
6
Claude Marcus 4
Author IdHAL : claude-marcus
Frédéric Burde
Author
Daniele Sommacale 3
Author
Michel Manfait 5
Author
Gerard Thiefin 6
Author
1
MEDyC - Matrice extracellulaire et dynamique cellulaire - UMR 7369 (Faculté de Médecine 51 Rue Cognacq-Jay 51095 REIMS CEDEX - France)
- SFR CAP Santé (Champagne-Ardenne Picardie Santé) (Faculté de Médecine de Reims, 51, rue Cognacq Jay, CS 30018,
51095 Reims Cedex - France)
- URCA - Université de Reims Champagne-Ardenne : FED 4231 (2 avenue Robert Schuman, 51100 Reims. - France)
- UPJV - Université de Picardie Jules Verne : FED 4231 (Chemin du Thil - 80000 Amiens - France)
- URCA - Université de Reims Champagne-Ardenne : UMR 7369 (2 avenue Robert Schuman, 51100 Reims. - France)
- CNRS - Centre National de la Recherche Scientifique : UMR 7369 (France)
2
Hôpital Jean Minjoz (France)
3
Service de Chirurgie Générale, Digestive et Endocrine [CHU Reims] (France)
- CHU Reims - Centre Hospitalier Universitaire de Reims (45, rue Cognacq-Jay 51100 Reims - France)
4
CHU Reims - Centre Hospitalier Universitaire de Reims (45, rue Cognacq-Jay 51100 Reims - France)
5
URCA - Université de Reims Champagne-Ardenne (2 avenue Robert Schuman, 51100 Reims.
- France)
6
Service d'hépatogastroentérologie (CHU Reims) (France)
- CHU Reims - Centre Hospitalier Universitaire de Reims (45, rue Cognacq-Jay 51100 Reims - France)
Abstract : This study evaluated the midterm delivery of doxorubicin in liver specimens from patients (N = 4) with hepatocellular carcinoma treated with drug-eluting embolic (DEE) transarterial chemoembolization. The patients had surgical resection 57, 79, 80 and 105 days after doxorubicin DEE chemoembolization. Doxorubicin concentrations inside embolic particles and in surrounding tissues were assessed by infrared microspectroscopy and microspectrofluorimetry, respectively. Embolic particles still contained doxorubicin and provided sustained drug delivery within targeted tissues 80 days after chemoembolization. Doxorubicin was undetectable after 105 days. In addition, aggregation of embolic particles inside vessel lumina was associated with slower doxorubicin elution and higher tissue concentrations when the number of aggregated embolic particles increased.
Document type :
Journal articles
Domain :
Complete list of metadata
https://hal.univ-reims.fr/hal-02929441
Contributor : Brigitte Perron <>
Submitted on : Thursday, September 3, 2020 - 2:26:32 PM
Last modification on : Monday, May 17, 2021 - 2:52:15 PM
Contributor : Brigitte Perron <>
Submitted on : Thursday, September 3, 2020 - 2:26:32 PM
Last modification on : Monday, May 17, 2021 - 2:52:15 PM
Identifiers
- HAL Id : hal-02929441, version 1
- DOI : 10.1016/j.jvir.2017.01.018
Citation
Hadrien D’inca, Olivier Piot, Marie-Danièle Diebold, Tullio Piardi, Claude Marcus, et al.. Doxorubicin Drug-Eluting Embolic Chemoembolization of Hepatocellular Carcinoma: Study of Midterm Doxorubicin Delivery in Resected Liver Specimens. JVIR: Journal of Vascular and Interventional Radiology, Elsevier, 2017, 28 (6), pp.804-810. ⟨10.1016/j.jvir.2017.01.018⟩. ⟨hal-02929441⟩
Metrics
Record views